Table 3.
Baseline data of the enrolled patients
| Study | Sample size | Age (years) | F/M | MELD score | Total bilirubin (mg/dl) | Child-Pugh score | Creatinine (mg/dl) | pH | Serum ionized calcium (mmol/l) |
|---|---|---|---|---|---|---|---|---|---|
| Schultheiss et al. [9] | 28 | 57 ± 11 | 8/20 | 36 ± 8.8 | 12 ± 14.7 | 12 ± 2.2 | 3.4 ± 2.0 | 7.29 ± 0.1 | 1.21 ± 0.08 |
| Lahmer et al. [10] | 24 | 59 | 4/20 | 35 ± 6.5 | 18.4 ± 14.5 | ≥ 10 | 3.8 ± 1.2 | 7.29 ± 0.05 | 1.14 ± 0.11 |
| Slowinski et al. [11] | 133 | 63 ± 15 | 38/95 | NR | 7.3 | NR | 2.8 ± 1.35 | 7.33 | 1.08 ± 0.12 |
| Sponholz et al. [18] | 89 | 54 ± 9.6 | 31/58 | NR | 7 ± 7.4 | NR | 2 ± 1.0 | 7.39 ± 0.07 | 1.11 ± 0.11 |
| Durao et al. [19] | 143 | 66 ± 16 | 59/84 | NR | NR | NR | 1.5 ± 0.88 | 7.29 ± 0.11 | 1.06 ± 0.06 |
| De Vico et al. [20] | 15 | 67.4 ± 11.9 | 5/10 | NR | 3.1 ± 3.38 | NR | 1.97 ± 0.88 | 7.38 ± 0.09 | 1.02 ± 0.06 |
| Saner et al. [21] | 68 | 47.1 ± 11.8 | 28/40 | 23.1 ± 9.1 | 8.7 ± 8.1 | NR | 2.35 ± 1.01 | 7.37 ± 0.08 | 1.08 ± 0.03 |
| Balogun et al. [22] | 697 | 56.4 | 281/416 | 17.7–44.81 | 11.4 | NR | ≥ 4 | NR | NR |
| Klingele et al. [23] | 69 | 59.1 ± 12.4 | 22/47 | 19.7 ± 9.6 | 9.5 ± 10.6 | NR | 2.7 ± 1.3 | NR | NR |
| Yu et al. [24] | 145 | 59 ± 17.7 | 92/53 | NR | NR | NR | 2.7 ± 3 | NR | NR |
| Summarized | 1411 | 57.9 | 568/843 | 25.2 ± 10.8 | 10.5 | Grade C | 2.44 ± 1.77 | 7.33 ± 0.1 | 1.08 ± 0.07 |
Abbreviations: F female, M male, MELD model of end-stage liver disease, NR not reported